Ellansé

**Ellansé** is a synthetic, injectable dermal filler composed of polycaprolactone (PCL) microspheres suspended in a carboxymethylcellulose (CMC) gel carrier, designed for subdermal implantation to provide immediate volume correction while stimulating neocollagenesis for long-term skin rejuvenation. Developed by AQTIS Medical BV (acquired by Sinclair Pharma in 2014) and CE-marked as an implantable medical device, it offers tunable longevity (e.g., Ellansé-S for 1 year, Ellansé-M for 2 years, Ellansé-L for 3-4 years, Ellansé-E for 4 years) through its STAT Technology™, with complete bioresorbability as the PCL microspheres degrade and are replaced by the patient's own collagen. Primarily indicated for adults over 18 to correct facial wrinkles, folds (e.g., nasolabial folds), volume loss, and aging signs in areas like cheeks, jawline, temples, hands, neck, and décolletage, clinical studies demonstrate sustained efficacy (e.g., ≥1-point WSRS improvement in 88-91% at 12 months) and high safety with low adverse event rates when administered by trained professionals.[1][2][3][5]

Brand names

EllanséEllansé-SEllansé-MEllansé-LEllansé-E